STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics, Inc. - BNGO STOCK NEWS

Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.

Bionano Genomics, Inc. (Nasdaq: BNGO) is a pioneering company in the life sciences instrumentation sector, dedicated to advancing genome biology understanding through innovative solutions. The company is renowned for its development and marketing of the Saphyr™ system, an ultra-sensitive platform designed for structural variation detection. This system enables researchers and clinicians to accelerate diagnostics and therapeutic target discovery, streamlining studies on chromosomal changes.

Bionano's core mission is to transform genomic analysis through optical genome mapping (OGM) solutions, diagnostic services, and software. Their flagship product, Saphyr™, offers unmatched capabilities in structural variation discovery and the ability to construct comprehensive genome assemblies. This technology is crucial for applications in cancer research, human disease studies, agricultural bioengineering, and genome discovery.

Recent achievements include the detection of unique structural variations and gene fusions in blood cancer samples, underscoring OGM's potential as a complement to traditional sequencing methods. Bionano's OGM technology has shown superior sensitivity and resolution in various studies, highlighting its utility in pediatric leukemia and other cancers.

The company operates globally with significant revenue from the Americas, and it generates product revenue from the sales of OGM and Ionic Purification systems and consumables. Bionano also offers diagnostic testing for neurodevelopmental disabilities through its Lineagen, Inc. d/b/a Bionano Laboratories business and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.

Partnerships with AI-driven companies like Diagens further enhance Bionano's offerings, aiming to improve reproductive health and other clinical applications. Additionally, Bionano continuously upgrades its VIA software and Bionano Solve pipeline to provide researchers with precise and sensitive genomic research tools.

For more information, visit Bionano Genomics and its associated websites, www.bionanolaboratories.com and www.purigenbio.com.

News

Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announces participation in AACR Annual Meeting 2024, showcasing optical genome mapping (OGM) applications in cancer research. The company introduces new Stratys™ system and previews VIA™ 7.1 software with enhanced capabilities for cancer research. Nine scientific posters will demonstrate OGM's utility in solid tumors, hematological malignancies, cell and gene therapy, and bioprocessing quality control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
none
-
News

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced a study on optical genome mapping in hereditary breast and ovarian cancer, revealing correlations between structural variations, mutated genes, and poor prognosis. OGM detected chromothripsis events and novel gene fusions accurately, potentially aiding in therapy decisions. The study sheds light on the impact of SV heterogeneity in HBOC-related cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
News

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) will participate in the ACMG Annual Clinical Genetics Meeting 2024, showcasing the Stratys™ system for optical genome mapping and presenting findings from early access customers. The event will feature presentations from renowned medical professionals and scientific workshops on OGM's utility in various research areas. Eleven scientific posters will be presented, covering applications in cancer, genetic disorders, and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
none
News

Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

Rhea-AI Summary
Bionano Genomics, Inc. reported a strong financial performance for Q4 2023 and FY 2023, with revenue growth of 30% over the previous year, reaching $10.7 million and $36.1 million, respectively. The company achieved significant milestones in OGM system installations and flowcell sales, indicating a 36% increase in installed systems and a 72% increase in flowcells sold compared to the previous year. Key product launches such as the Stratys system and VIA software have been well-received, driving revenue growth. Bionano also saw positive clinical validation results for OGM in prenatal and postnatal studies. The company aims to continue its success in 2024 by focusing on core OGM products, anticipating revenue in the range of $37.0 to $41.0 million for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
earnings
-
News

Bionano to Present at TD Cowen’s 44th Annual Health Care Conference

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced that Erik Holmlin, CEO, will present at TD Cowen's Health Care Conference on March 6, 2024. The webcast will be available on their website for 30 days post-conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
-
News

Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) will host a conference call to report financial results for Q4 and year end 2023, highlighting recent corporate progress. The call will take place on March 5, 2024, at 4:30 p.m. ET. Participants can access the live webcast on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences earnings
News

Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway

Rhea-AI Summary
Bionano Genomics, Inc. announces an amendment to reduce outstanding debt through convertible notes, providing immediate access to $30.0 million of near-term liquidity. The company aims to expand capital and reduce debt on its balance sheet, enhancing financial flexibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
News

American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announces the inclusion of optical genome mapping (OGM) in the ACMG technical laboratory standards for solid tumor analysis. OGM's high-resolution detection of structural variants is highlighted, emphasizing its utility in genome-wide analysis for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
News

Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced that its CEO will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024. Interested parties can schedule a meeting with Bionano through their BTIG representative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
conferences
News

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Rhea-AI Summary
Bionano Genomics, Inc. concluded its 2024 Symposium, featuring 32 oral presentations and 69 scientific posters from 92 countries. The event showcased the potential of optical genome mapping (OGM) in research applications for hematologic malignancies, genetic diseases, and cell and gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none

FAQ

What is the current stock price of Bionano Genomics (BNGO)?

The current stock price of Bionano Genomics (BNGO) is $0.2514 as of November 25, 2024.

What is the market cap of Bionano Genomics (BNGO)?

The market cap of Bionano Genomics (BNGO) is approximately 24.2M.

What does Bionano Genomics, Inc. specialize in?

Bionano Genomics specializes in genome analysis solutions, particularly through their Saphyr™ system for structural variation detection.

What is the Saphyr™ system?

The Saphyr™ system is Bionano's high-speed, high-throughput whole genome mapping solution that offers unmatched structural variation discovery capabilities.

What are the applications of Bionano's OGM technology?

Bionano's OGM technology is used in cancer research, human disease studies, agricultural bioengineering, and genome discovery.

What recent achievements has Bionano reported?

Bionano recently reported detecting unique structural variations and gene fusions in blood cancer samples, showcasing OGM's potential as a complement to traditional sequencing methods.

Where does Bionano operate?

Bionano operates globally with significant revenue generated from the Americas, EMEA, and Asia Pacific regions.

What additional services does Bionano offer?

Bionano offers diagnostic testing for neurodevelopmental disabilities and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.

Who are Bionano's key partners?

Bionano partners with companies like Diagens to enhance clinical applications, particularly in reproductive health.

What is the purpose of Bionano's VIA software?

Bionano's VIA software provides researchers with precise and sensitive tools for genomic research, improving visualization, interpretation, and reporting of results.

Are Bionano's products for research or clinical use?

Most of Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

How can I learn more about Bionano Genomics?

You can visit Bionano's main website at www.bionano.com or its associated websites, www.bionanolaboratories.com and www.purigenbio.com, for more information.

Stock BNGO logo
Bionano Genomics, Inc.

Nasdaq:BNGO

BNGO Rankings

#5222 Ranked by Market Cap
N/A Ranked by Dividends

BNGO Stock Data

24.17M
101.87M
0.15%
12.81%
10.25%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO